Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24:38–69.

Article  PubMed  Google Scholar 

Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–54.

Article  PubMed  CAS  Google Scholar 

Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385–91.

Article  PubMed  CAS  Google Scholar 

Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.

Article  PubMed  CAS  Google Scholar 

Milano W, Colletti C, Capasso A. Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach. Endocr Metab Immune Disord. 2017;17(1):38–55.

CAS  Google Scholar 

Takechi K, Yoshioka Y, Kawazoe H, et al. Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders. Biol Pharm Bull. 2017;40(10):1775–8.

Article  PubMed  CAS  Google Scholar 

Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ (Clin Res Ed). 2002;324(7332):250–2.

Article  Google Scholar 

Bushe C, Shaw M, Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol (Oxf, Engl). 2008;22:46–55.

Article  Google Scholar 

Besnard I, Auclair V, Callery G, et al. Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance. Encephale. 2014;40(1):86–94.

Article  PubMed  CAS  Google Scholar 

Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.

Article  PubMed  CAS  Google Scholar 

Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhu Y, Zhang C, Siafis S, et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr Res. 2021;237:20–5.

Article  PubMed  CAS  Google Scholar 

Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208–24.

Article  PubMed  PubMed Central  Google Scholar 

Wallach JD, Sullivan PG, Trepanowski JF, et al. Sex based subgroup differences in randomized controlled trials: empirical evidence from cochrane meta-analyses. BMJ (Clin Res Ed). 2016;355: i5826.

Google Scholar 

Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008. https://doi.org/10.1177/0269881107087346.

Article  PubMed  Google Scholar 

Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78.

Article  PubMed  Google Scholar 

Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(Suppl 1):S90–4.

Article  PubMed  PubMed Central  Google Scholar 

Luykx JJ, Correll CU, Manu P, et al. Pneumonia risk, antipsychotic dosing, and anticholinergic burden in schizophrenia. JAMA Psychiatr. 2024;81(10):967–75.

Article  Google Scholar 

Taipale H, Tanskanen A, Correll CU, et al. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022;9(4):271–9.

Article  PubMed  Google Scholar 

Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25–34.

Article  PubMed  CAS  Google Scholar 

Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ Can Med Assoc J. 2003;169(6):575–81.

Google Scholar 

Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.

PubMed  PubMed Central  CAS  Google Scholar 

Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (fin20). World Psychiatry. 2020;19(1):61–8.

Article  PubMed  PubMed Central  Google Scholar 

Roth AJ. Multiple comparison procedures for discrete test statistics. J Stat Plann Inference. 1999;82(1–2):101–17.

Article  Google Scholar 

Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol (Oxf, Engl). 2008;22(2 Suppl):12–9.

Article  Google Scholar 

Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006625. https://doi.org/10.1002/14651858.CD006625.pub2.

Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291–314.

Article  PubMed  CAS  Google Scholar 

Riedel M, Müller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):432–7.

Article  PubMed  Google Scholar 

Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340–6.

Article  PubMed  CAS  Google Scholar 

Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf. 2011;10(3):437–48.

Article  PubMed  CAS  Google Scholar 

Galbally M, Wynter K, Siskind D, et al. Sex differences between female and male individuals in antipsychotic efficacy and adverse effects in the treatment of schizophrenia. CNS Drugs. 2024;38(7):559–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51(4):317–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Retief M, Chiliza B, Phahladira L, et al. Prolactin, flupenthixol decanoate and first episode schizophrenia—clinical and laboratory correlates. Metab Brain Dis. 2019;34(6):1679–87.

Article  PubMed  CAS  Google Scholar 

Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopha